EP Patent

EP1023051B1 — Oral morphine multiparticulate formulation

Assigned to Lkermes Pharma Ireland Ltdconnaught House 1 Burli · Expires 2003-05-07 · 23y expired

What this patent protects

An oral morphine multiparticulate formulation for once-daily administration to a patient, comprising sustained release particles each having a core containing water soluble morphine and an osmotic agent, the core being coated with a rate-controlling polymer coat comprised of ammo…

USPTO Abstract

An oral morphine multiparticulate formulation for once-daily administration to a patient, comprising sustained release particles each having a core containing water soluble morphine and an osmotic agent, the core being coated with a rate-controlling polymer coat comprised of ammonio methacrylate copolymers in an amount sufficient to achieve therapeutically effective plasma levels of morphine over at least 24 hours in the patient.

Drugs covered by this patent

Patent Metadata

Patent number
EP1023051B1
Jurisdiction
EP
Classification
—
Expires
2003-05-07
Drug substance claim
No
Drug product claim
No
Assignee
Lkermes Pharma Ireland Ltdconnaught House 1 Burli
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.